The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

AGM Statement and Result of AGM

25 Apr 2017 13:34

RNS Number : 2782D
Proteome Sciences PLC
25 April 2017
 

 

 

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

AGM Statement and Result of AGM

 

At the Company's AGM held today the Chairman, Christopher Pearce, made the following statement:

 

"As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences. The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations."

 

All resolutions at the AGM were duly passed.

 

 

For further information:

 

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)1932 865065

Dr Ian Pike, Chief Scientific Officer

 

Geoff Ellis, Finance Director

 

finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson

 

 

Tel: +44 (0)20 7220 0500

Tony Quirke (broking)

 

IFC Advisory (Financial PR and IR)

Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3053 8671

 

 

Notes for editors:

 

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

 

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

 

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMPGUGWCUPMGPA

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.